Literature DB >> 31598772

[T-cell immune responses in chronic inflammatory diseases of the nasal mucosa].

L Klimek1, I Casper2, S Siemer3, B Wollenberg4, R Stauber3, M Koennecke4.   

Abstract

Acute rhinosinusitis and chronic rhinosinusitis are inflammatory diseases of the mucosal membranes due to mislead immunological reactions to aeroallergens. T‑cells are divided into different groups based on their cytokine secretion: T‑helper type 1 (Th1) and type 2 (Th2) cells. The allergic immune response is caused by activation of specific Th2 cells. With specific immunotherapy, the mislead hyperactivated "allergic" immune response is reduced to a reaction within the normal range. The inflammatory forms of chronic rhinosinusitis are called endotypes, and, in the future, could enable a targeted, pathomechanistic therapy. These endotype-based treatment approaches target specific signaling pathways that have already shown good effects for chronic rhinosinusitis with nasal polyps using monoclonal antibodies. However, so far, only selected patients with non-rhinologic indications, off-label treatments, or in clinical trials have benefited from these treatments.

Entities:  

Keywords:  Allergy; B‑lymphocytes; Immunotherapy; T‑cell receptor; T‑lymphocytes

Mesh:

Substances:

Year:  2019        PMID: 31598772     DOI: 10.1007/s00106-019-00759-2

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  46 in total

1.  Apoptosis and loss of adhesion of bronchial epithelial cells in asthma.

Authors:  Axel Trautmann; Katja Kruger; Mubeccel Akdis; Dietrich Muller-Wening; Ahmet Akkaya; Eva-B Brocker; Kurt Blaser; Cezmi A Akdis
Journal:  Int Arch Allergy Immunol       Date:  2005-09-22       Impact factor: 2.749

2.  Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism.

Authors:  W Ouyang; S H Ranganath; K Weindel; D Bhattacharya; T L Murphy; W C Sha; K M Murphy
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

3.  Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells.

Authors:  H Kurata; H J Lee; A O'Garra; N Arai
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

4.  Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids.

Authors:  G Cox; T Ohtoshi; C Vancheri; J A Denburg; J Dolovich; J Gauldie; M Jordana
Journal:  Am J Respir Cell Mol Biol       Date:  1991-06       Impact factor: 6.914

Review 5.  Mechanisms of allergen-specific immunotherapy.

Authors:  Cezmi A Akdis; Kurt Blaser; Mübeccel Akdis
Journal:  Chem Immunol Allergy       Date:  2006

Review 6.  New insights into the mechanisms of allergen-specific immunotherapy.

Authors:  Carsten B Schmidt-Weber; Kurt Blaser
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-12

7.  Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge.

Authors:  S Rak; M R Jacobson; R M Sudderick; K Masuyama; S Juliusson; A B Kay; Q Hamid; O Löwhagen; S R Durham
Journal:  Clin Exp Allergy       Date:  1994-10       Impact factor: 5.018

8.  Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene.

Authors:  K Shimoda; J van Deursen; M Y Sangster; S R Sarawar; R T Carson; R A Tripp; C Chu; F W Quelle; T Nosaka; D A Vignali; P C Doherty; G Grosveld; W E Paul; J N Ihle
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

Review 9.  Micro and Nano Material Carriers for Immunomodulation.

Authors:  E Bracho-Sanchez; C Q Xia; M J Clare-Salzler; B G Keselowsky
Journal:  Am J Transplant       Date:  2016-06-27       Impact factor: 8.086

Review 10.  Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities.

Authors:  Michael Koennecke; Ludger Klimek; Joaquim Mullol; Philippe Gevaert; Barbara Wollenberg
Journal:  Allergo J Int       Date:  2018-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.